The expanded ATM facility creates a persistent overhang; monitor daily volume and TD Cowen's selling activity for signs of accelerated distribution. With high short interest, any positive pipeline catalyst could trigger a squeeze, but the ATM cap increase suggests management expects to need more cash, likely capping near-term upside.
TYRA drugs
TYRA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 5 $25.71entry
- T+1 · 3mo ago +4.86%α +5.02% · $26.96
- T+5 · 3mo ago −1.59%α −1.95% · $25.30
- T+20 · 3mo ago −2.26%α −1.65% · $25.13
- T+60 · 19d ago −17.37%α −17.56% · $21.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tyra Biosciences has amended its existing at-the-market (ATM) equity offering agreement with TD Cowen, increasing the maximum aggregate offering amount from $150 million to $250 million after fully utilizing the prior $150 million capacity. The filing signals ongoing dilution risk for existing shareholders as the company continues to access the public equity markets for capital, likely to fund its clinical-stage pipeline. With a $1.9B market cap and high short interest (~16.7%), the market may view this expanded ATM capacity as a near-term overhang on the stock.
Key Facts
- Tyra Biosciences has fully utilized its prior $150 million ATM facility and amended the agreement to allow up to $250 million in total common stock sales.
- The amendment was entered into on August 4, 2026, and the last reported sale price on August 3, 2026 was $32.04 per share.
- The company is a clinical-stage biopharmaceutical firm with no disclosed revenue in this filing, relying on equity offerings for capital.
- Short interest is approximately 16.7% of estimated shares outstanding as of mid-July 2026, indicating significant bearish positioning.
Financial Impact
Potential dilution of up to ~$100 million in additional common stock sales beyond the already-exhausted $150 million facility, representing roughly 5-8% of current market cap at the $32.04 reference price.
Risk Factors
- Continued dilution from ATM sales may pressure the stock price.
- Clinical-stage biotech with no revenue; capital needs are uncertain and may require further equity raises.
- High short interest could amplify downside if the ATM is used aggressively.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-333055 |
| Document: 0001193125-26-333055-index-headers.html | 0001193125-26-333055 |
| Document: 0001193125-26-333055-index.html | 0001193125-26-333055 |
| Document: 0001193125-26-333055.txt | 0001193125-26-333055 |
Track record
13 reports on TYRA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Viewing Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers